Privately held Zavante Therapeutics Inc. hopes to push the antibiotics envelope a bit further after its single agent, Zolyd (fosfomycin for injection, previously ZTI-01), met the primary endpoint of statistical noninferiority to piperacillin/tazobactam (Zosyn, Pfizer Inc.) at the highest approved dose in the pivotal phase II/III ZEUS trial in patients with complicated urinary tract infections (cUTI), including acute pyelonephritis (AP).